


## m-PEG-NHS ester (MW 40000)

Cat. No.:	HY-157745
CAS No.:	92451-01-9
Molecular Formula:	$(C_2H_4O)_n C_7H_9NO_5$
Target:	Liposome
Pathway:	Metabolic Enzyme/Protease
Storage:	-20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (ultrasonic and warming and heat to 60°C)
In Vivo	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: <math>\geq 2.5</math> mg/mL (Infinity mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-<math>\beta</math>-CD in saline) Solubility: <math>\geq 2.5</math> mg/mL (Infinity mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: <math>\geq 2.5</math> mg/mL (Infinity mM); Clear solution</li> </ol>

### BIOLOGICAL ACTIVITY

Description	m-PEG-NHS ester (MW 40000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects <sup>[1]</sup> .
-------------	--

### REFERENCES

[1]. Jin M, et al. Preparation of pegylated lumbrokinase and an evaluation of its thrombolytic activity both in vitro and in vivo. *Acta Pharmaceutica Sinica B*. 2013, 3(2): 123-129.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA